Primary Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
Top Cited Papers
- 15 May 2003
- journal article
- pediatric oncology
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (10), 2011-2018
- https://doi.org/10.1200/jco.2003.08.132
Abstract
Purpose: To determine demographic data and define prognostic factors for long-term outcome in patients presenting with high-grade osteosarcoma of bone with clinically detectable metastases at initial presentation. Patients and Methods: Of 1,765 patients with newly diagnosed, previously untreated high-grade osteosarcomas of bone registered in the neoadjuvant Cooperative Osteosarcoma Study Group studies before 1999, 202 patients (11.4%) had proven metastases at diagnosis and therefore were enrolled onto an analysis of demographic-, tumor-, and treatment-related variables, response, and survival. The intended therapeutic strategy included pre- and postoperative multiagent chemotherapy as well as aggressive surgery of all resectable lesions. Results: With a median follow-up of 1.9 years (5.5 years for survivors), 60 patients were alive, 37 of whom were in continuously complete surgical remission. Actuarial overall survival rates at 5 and 10 (same value for 15) years were 29% (SE = 3%) and 24% (SE = 4%), respectively. In univariate analysis, survival was significantly correlated with patient age, site of the primary tumor, number and location of metastases, number of involved organ systems, histologic response of the primary tumor to preoperative chemotherapy, and completeness and time point of surgical resection of all tumor sites. However, after multivariate Cox regression analysis, only multiple metastases at diagnosis (relative hazard rate [RHR] = 2.3) and macroscopically incomplete surgical resection (RHR = 2.4) remained significantly associated with inferior outcomes. Conclusion: The number of metastases at diagnosis and the completeness of surgical resection of all clinically detected tumor sites are of independent prognostic value in patients with proven primary metastatic osteosarcoma.Keywords
This publication has 31 references indexed in Scilit:
- Phase II/III Trial of Etoposide and High-Dose Ifosfamide in Newly Diagnosed Metastatic Osteosarcoma: A Pediatric Oncology Group TrialJournal of Clinical Oncology, 2002
- Presurgical Window of Carboplatin and Surgery and Multidrug Chemotherapy for the Treatment of Newly Diagnosed Metastatic or Unresectable Osteosarcoma: Pediatric Oncology Group TrialJournal of Pediatric Hematology/Oncology, 2001
- Carboplatin/Ifosfamide Window Therapy for Osteosarcoma: Results of the St Jude Children’s Research Hospital OS-91 TrialJournal of Clinical Oncology, 2001
- Neoadjuvant Chemotherapy for Patients with Synchronous Multifocal Osteosarcoma: Results in Eleven CasesJournal of Chemotherapy, 2001
- Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.Oncology Reports, 2000
- A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcomaAnnals of Oncology, 1999
- Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study.Journal of Clinical Oncology, 1998
- Prognosis of Osteosarcoma With Pulmonary Metastases at Initial Presentation Is Not DismalClinical Orthopaedics and Related Research, 1998
- 556: Metastatic osteogenic sarcoma (OS) at diagnosis. Study of 73 cases from the french society of pediatric oncology (SFOP) between 1980 and 1990European Journal of Cancer, 1997
- Osteogenic sarcoma with clinically detectable metastasis at initial presentation.Journal of Clinical Oncology, 1993